Lenalidomid Grindeks

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an Immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is used to treat certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Grindeks is an immunomodulatory agent indicated for several hematologic malignancies.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic syndromes (MDS): reduces transfusion dependence and delays transformation to acute leukemia. Mantle cell lymphoma: contributes to disease control when used in combination therapy for relapsed cases.

Lenalidomid Grindeks may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: decreased white blood cell count. - Thrombocytopenia: reduced platelet levels. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in veins. - Severe neutropenia: heightened infection risk. - Severe thrombocytopenia: increased bleeding risk. - Secondary primary malignancies: new cancers. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatotoxicity: liver enzyme elevation.

Lenalidomid Grindeks requires careful monitoring and specific safety measures.

Pregnancy: Category X – contraindicated; ensure effective contraception. Thrombosis risk: assess patient history before initiating therapy. Blood counts: perform regular CBC monitoring to detect cytopenias. Renal impairment: adjust dose in patients with reduced kidney function. Drug interactions: review concomitant medications for potential CYP effects. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Lenalidomid Grindeks can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin): can lower lenalidomide exposure. - Thalidomide: additive teratogenic potential.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate renal toxicity. - Antibiotics (e.g., fluoroquinolones): potential for enhanced myelosuppression. - Live vaccines: risk of infection due to immunosuppression. - Digoxin: possible alteration of serum levels.